Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Clinical PK/PD study of TxA2 antagonist

July 28, 1997

Joint venture established for transgenic ATIII

July 25, 1997

Microbix receives milestone payment under ThromboClear agreement with Gensia

July 25, 1997

Novel fibrinogen/integrin receptor antagonists described by Merck KGaA

July 22, 1997

DuPont Merck prepares anticoagulant aminoboronic acids

July 21, 1997

Fibrinogen-antagonistic oxopiperazine derivatives from Yamanouchi

July 17, 1997

Potent, orally active fibrinogen antagonist developed at Merck & Co.

July 17, 1997

Texas Biotechnology initiates NDA filing for Novastan

July 16, 1997

Merck & Co. develops potent and selective pyridinone acetamide thrombin inhibitor

July 16, 1997

Lp(a)-dependent actions of LMWH

July 14, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...